SEIKAGAKU CORP.

Products

Category

Product

Brand

Description

Hyaluronic Acid in Healthcare (PHM284A)

Gel-One		A single injection of cross-linked HA treatment for osteoarthritis of the knee. The product is marketed as HyLink in Taiwan and Italy and as ARTZ in China. Zimmer Biomet holds the exclusive distribution rights for Gel-One in the U.S. Gel-One initiated Phase III clinical studies of the knee joint and hip joint in February 2025.
VISCO-3		A three-injection high molecular weight hyaluronate for osteoarthritis of the knee. Zimmer Biomet holds the exclusive distribution rights for VISCO-3 Sodium Hyaluronate in the U.S.
SUPARTZ FX		A five-injection HA therapy for the treatment of knee osteoarthritis. Bioventus has the exclusive distribution rights for SUPARTZ FX in the US through May 2028.

This information is available for BCC Research members only.

Already a Member? Sign In Become a Member

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment